Division of Sanofi
Latest From Chattem Inc.
French pharma's worldwide OTC drug and other consumer health product sales grow 4.1% to $1.3bn led by more than 10% growth in its emerging markets, but US sales fell nearly 6% partly due to market-share incursion by private label OTCs.
Sales of dietary supplements promoted for nutritional needs of diabetics are exploding as consumers seek non-drug products to deal with symptoms of the disease, says a consumer health analyst in a recent presentation. Consumer health products positioned to prevent disease are growing at a much faster rate globally than those formulas that treat ailments.
Claims that Sanofi's Xyzal 24 HR OTC product contains the same effectiveness as competitor Zyrtec but with half the medication fail a US
National Advertising Division review. NAD also recommended modifying claims suggesting Xyzal's pharmacological design confers a clinically meaningful benefit over Zyrtec.
- OTC, Consumer
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Senior Management
- Contact Info
Phone: (615) 821-4571
1715 West 38th St.
P.O. Box 2219 Chattanooga, TN 37409
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.